USMBA-NLP at SemEval-2024 Task 2: Safe Biomedical Natural Language Inference for Clinical Trials using Bert
Anass Fahfouh, Abdessamad Benlahbib, Jamal Riffi, Hamid Tairi
Abstract
This paper presents the application of BERT inSemEval 2024 Task 2, Safe Biomedical Natu-ral Language Inference for Clinical Trials. Themain objectives of this task were: First, to in-vestigate the consistency of BERT in its rep-resentation of semantic phenomena necessaryfor complex inference in clinical NLI settings.Second, to investigate the ability of BERT toperform faithful reasoning, i.e., make correctpredictions for the correct reasons. The submit-ted model is fine-tuned on the NLI4CT dataset,which is enhanced with a novel contrast set,using binary cross entropy loss.- Anthology ID:
- 2024.semeval-1.66
- Volume:
- Proceedings of the 18th International Workshop on Semantic Evaluation (SemEval-2024)
- Month:
- June
- Year:
- 2024
- Address:
- Mexico City, Mexico
- Editors:
- Atul Kr. Ojha, A. Seza Doğruöz, Harish Tayyar Madabushi, Giovanni Da San Martino, Sara Rosenthal, Aiala Rosá
- Venue:
- SemEval
- SIG:
- SIGLEX
- Publisher:
- Association for Computational Linguistics
- Note:
- Pages:
- 432–436
- Language:
- URL:
- https://aclanthology.org/2024.semeval-1.66
- DOI:
- Cite (ACL):
- Anass Fahfouh, Abdessamad Benlahbib, Jamal Riffi, and Hamid Tairi. 2024. USMBA-NLP at SemEval-2024 Task 2: Safe Biomedical Natural Language Inference for Clinical Trials using Bert. In Proceedings of the 18th International Workshop on Semantic Evaluation (SemEval-2024), pages 432–436, Mexico City, Mexico. Association for Computational Linguistics.
- Cite (Informal):
- USMBA-NLP at SemEval-2024 Task 2: Safe Biomedical Natural Language Inference for Clinical Trials using Bert (Fahfouh et al., SemEval 2024)
- PDF:
- https://preview.aclanthology.org/jeptaln-2024-ingestion/2024.semeval-1.66.pdf